dc.contributor.author | Schuster, Cornelia | en_US |
dc.contributor.author | Eikesdal, Hans Petter | en_US |
dc.contributor.author | Puntervoll, Hanne | en_US |
dc.contributor.author | Geisler, Jürgen | en_US |
dc.contributor.author | Geisler, Stephanie | en_US |
dc.contributor.author | Molven, Anders | en_US |
dc.contributor.author | Akslen, Lars A. | en_US |
dc.date.accessioned | 2013-04-08T11:44:23Z | |
dc.date.available | 2013-04-08T11:44:23Z | |
dc.date.issued | 2012-06-15 | eng |
dc.Published | PLoS ONE 7(6): e38364 | eng |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/1956/6486 | |
dc.description.abstract | Background: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of bevacizumab monotherapy in patients with metastatic melanoma. Methods and Findings: Thirty-five patients with metastatic melanoma in progression were enrolled in this phase II, single arm clinical trial. Each patient received bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression occurred. Clinical efficacy was evaluated as objective response, disease control (DC), and survival. We observed one complete (3%) and 5 partial (14%) responses. In addition, 5 patients experienced stable disease >6 months (14%) while 24 patients had progressive disease (PD, 69%), corresponding to a total DC at 6 months in 11 out of 35 patients (31%). Median progression free survival (PFS) was 2.14 months and median overall survival (OS) was 9 months (1.12–49). Seven of the 11 patients experiencing DC developed early hypertension (<2 months) compared to 3/24 of patients with PD (P = 0.001), and hypertension was associated with PFS (P = 0.005) and OS (P = 0.013). Conclusion: Bevacizumab monotherapy demonstrated promising clinical efficacy in patients with metastatic melanoma with disease control in 31% of the patients. Induced early hypertension was a marker for clinical efficacy of bevacizumab. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Public Library of Science | eng |
dc.relation.ispartof | <a href="http://hdl.handle.net/1956/15572" target="blank">Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab</a> | |
dc.rights | Attribution CC BY | eng |
dc.rights.uri | http://creativecommons.org/licenses/by/2.5/ | eng |
dc.title | Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2012 Schuster et al. | |
dc.identifier.doi | https://doi.org/10.1371/journal.pone.0038364 | |
dc.identifier.cristin | 945372 | |